Adverse drug events observed with 150 mg versus 300 mg secukinumab for the treatment of moderate to severe plaque psoriasis: A systematic review and meta-analysis

BACKGROUND: Secukinumab has been approved for the treatment of moderate to severe plaque psoriasis. However, safety measures concerning drug administration is vital during treatment. Understanding the right way to administer drugs is important to reduce any serious adverse drug event. In this analys...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Li, Yang, Hua, Chen, Qihong, Zhao, Jing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2019
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6336633/
https://www.ncbi.nlm.nih.gov/pubmed/30633199
http://dx.doi.org/10.1097/MD.0000000000014042

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6336633/
https://www.ncbi.nlm.nih.gov/pubmed/30633199
http://dx.doi.org/10.1097/MD.0000000000014042

Ejemplares similares